<DOC>
	<DOCNO>NCT02014051</DOCNO>
	<brief_summary>The purpose study investigate tolerability SyB C-1101 orally administer twice daily 14 consecutive day patient recurrent/relapsed refractory myelodysplastic syndrome , determine dose-limiting toxicity maximum tolerate dose , estimate recommend dose phase II study . Pharmacokinetics antitumor effect also investigate .</brief_summary>
	<brief_title>Safety Pharmacokinetics Study SyB C-1101 Patients With Recurrent/Relapsed Refractory Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>In Cohort 1 , SyB C-1101 280 mg/dose group , Participants administer 280 mg/dose SyB C-1101 twice daily orally 14 consecutive day , follow 7-day observation period . In Cohort 2 , SyB C-1101 560 mg/dose group , Participants administer 560 mg/dose SyB C-1101 twice daily orally 14 consecutive day , follow 7-day observation period . In Cohorts , treatment period 21 day constitute 1 cycle , treatment allow cycle . The participant receive SyB C-1101 daily Day 1 Day 14 Cycle 1 investigation pharmacokinetics .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Patients must satisfy follow condition list : 1 . Patients histologically document cytologically confirm myelodysplastic syndrome ( MDS ) , find meet follow criterion basis World Health Organization ( WHO ) classification FrenchAmericanBritish ( FAB ) classification . Refractory Anemia ( RA ) * ( &lt; 5 % myeloblast , &lt; 15 % ringed sideroblast ) RA Ring Sideroblasts ( RARS ) * ( &lt; 5 % myeloblast , &gt; = 15 % ringed sideroblast ) RA Excess Blasts1 ( RAEB1 ) ( 5 % 9 % myeloblast ) RAEB2 ( 10 % 19 % myeloblast ) RAEBt ( 20 % 29 % myeloblast &lt; 25,000/mm^3 peripheral leukocyte ) Chronic myelomonocytic leukemia ( CMML ) ( 10 % 19 % myeloblast , &gt; = 1,000/mm^3 peripheral monocyte , &lt; 13,000/mm^3 leukocyte ) * RA RARS patient 2 unit erythrocyte transfusion within 8 week . 2 . Patients low value least one blood cell lineage ( least one follow cytopenia ) . Neutrophils : &lt; 1,800/mm^3 Platelets : &lt; 100,000/mm^3 Hemoglobin : &lt; 10 g/dL 3 . Patients previous history chemotherapy ( include immunosuppressive therapy , anabolic steroid lenalidomide ) target disease meet follow criterion . Patients achieve complete remission , partial remission , hematologic improvement . * Patients recurrence/relapse complete remission , partial remission , hematologic improvement . * Patients intolerability lead discontinuation treatment development liver dysfunction , kidney dysfunction , etc. , start treatment . *Proximate therapeutic efficacy judge International Working Group ( IWG ) 2006 criterion . 4 . For patient receive chemotherapy immunosuppressive therapy , anabolic steroid lenalidomide , patient treat four week longer end previous therapy judge residual effect ( antitumor effect ) previous therapy . 5 . Patients expect survive least three month longer . 6 . Patients least 20 year old ( informed consent obtain ) . 7 . Patients score 0 2 The Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) . 8 . Patients adequate function major organ ( heart , lung , liver , kidney , etc. ) . Aspartate aminotransferase ( AST ) : great 3.0 time upper boundary reference range institution Alanine aminotransferase ( ALT ) : great 3.0 time upper boundary reference range institution Total bilirubin : 1.5 time upper boundary reference range institution Serum creatinine : 1.5 time upper boundary reference range institution ECG : abnormal finding require treatment Echocardiography : abnormal finding require treatment 9 . Patients personally sign informed consent document participation study . Patients satisfy follow condition enrol study . 1 . Patients anemia caused factor MDS ( hemolytic anemia , gastrointestinal ( GI ) bleeding , etc . ) 2 . Patients hypoplasia MDS ( &lt; 10 % osteocyte density ) 3 . Patients undergone treatment active malignant tumor within past year ( except basal cell squamous cell skin cancer , primary squamous cell carcinoma cervix noninvasive breast cancer ) . 4 . Patients administer cytokine preparation GCSF ( granulocytecolony stimulate factor ) , erythropoietin , etc . within 14 day test enrollment study . 5 . Patients obvious infectious disease ( include viral infection ) . 6 . Patients serious complication ( liver failure , renal failure , etc. ) . 7 . Patients complication previous history serious heart disease ( myocardial infarction , ischemic heart disease , etc . ) within past two year enrollment , cardiac arrhythmia require treatment . 8 . Patients serious gastrointestinal condition ( severe significant nausea/vomiting , diarrhea , etc . ) 9 . Patients positive Hepatitis B surface ( HBs ) antigen HIV antibody . 10 . Patients serious bleed tendency ( disseminate intravascular coagulation ( DIC ) , internal hemorrhage , etc. ) . 11 . Ascites pleural fluid require active medical management include paracentesis , hyponatremia ( define serum sodium value &lt; 130 mEq/L ) . 12 . Patients administered drug clinical trial unapproved drug within three month enrollment . 13 . Patients previously treat test drug ( rigosertib sodium ) . 14 . Patients know allergy polyethylene glycol gelatin capsule . 15 . Patients addiction legal illegal drug , alcohol dependency . 16 . Patients pregnant may become pregnant , lactate mother . 17 . Patients consent follow contraceptive measure . Patients avoid sexual intercourse sexual partner use follow contraceptive method time period : male patient administration period trial six month end administration ; female patient administration period trial , second menstrual period confirm end administration ( case female patient menstrual period , two month end administration ) . Male patient : Patients always use condom . For effective contraception , recommend female partner also use contraceptive method female patient . Female patient : Female patient may become pregnant use one type follow contraceptive method . In addition , male partner always use condom . Oral contraceptive ( birth control pill ) , Intrauterine device ( IUD ) , Tubal ligation 18 . Other patient judge unsuitable investigator subinvestigators .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>